{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:10Z","timestamp":1788798430991,"version":"build-2803163510"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,11]]},"DOI":"10.18632\/oncotarget.15989","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T18:41:51Z","timestamp":1488998511000},"page":"25433-25441","source":"Crossref","is-referenced-by-count":26,"title":["Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer"],"prefix":"10.18632","volume":"8","author":[{"given":"Luigi","family":"Cormio","sequence":"first","affiliation":[{"name":"Department of Urology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cormio","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Massenio","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Pedicillo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cagiano","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cal\u00f2","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pagliarulo","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantaleo","family":"Bufo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer Statistics, 2015","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Bray","year":"2013","journal-title":"Eur J Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3346\/jkms.2008.23.3.428","article-title":"Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder","volume":"23","author":"HJ;","year":"2008","journal-title":"J Korean Med Sci"},{"key":"4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Fair","year":"1997","journal-title":"J Urol"},{"key":"5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival","volume":"169","author":"Studer","year":"2003","journal-title":"J Urol"},{"key":"6","article-title":"Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS)","author":"Zigeuner","year":"2015","journal-title":"EAU"},{"key":"7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/10408363.2014.930412","article-title":"Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?","volume":"51","author":"Cormio","year":"2014","journal-title":"Crit Rev Clin Lab Sci"},{"key":"8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3109\/10408363.2015.1033610","article-title":"Molecular markers in bladder cancer: Novel research frontiers","volume":"52","author":"Cormio","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Mangu","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","article-title":"HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment","volume":"20","author":"Pai","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"Vieillefond","year":"2010","journal-title":"Ann Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab - mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Bast","year":"2007","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2003.08.027","article-title":"HER2\/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?","volume":"40","author":"Bartlett","year":"2004","journal-title":"Eur J Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urolonc.2006.08.021","article-title":"Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?","volume":"26","author":"Mansson","year":"2008","journal-title":"Urol Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1586\/era.11.58","article-title":"Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues","volume":"11","author":"Witjes","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/mc.2940030503","article-title":"Amplification and expression of the c-erb B2\/neu protooncogene in human bladder cancer","volume":"3","author":"Hung","year":"1990","journal-title":"Mol Carcinog"},{"key":"18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","article-title":"Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression","volume":"66","author":"Pan","year":"2013","journal-title":"J Clin Pathol"},{"key":"19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/00365599.2011.637955","article-title":"HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder","volume":"46","author":"Jahnson","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","article-title":"Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups","volume":"33","author":"Ding","year":"2015","journal-title":"World J Urol"},{"key":"21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4081\/aiua.2013.2.73","article-title":"HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3)","volume":"85","author":"Pierconti","year":"2013","journal-title":"Arch It Urol Androl"},{"key":"22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","article-title":"Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours","volume":"41","author":"Lobel","year":"2002","journal-title":"Eur Urol"},{"key":"23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.juro.2006.09.038","article-title":"Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma","volume":"177","author":"Lotan","year":"2007","journal-title":"J Urol"},{"key":"24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.urolonc.2008.08.003","article-title":"Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherpay in patients with T1G3 bladder cancer","volume":"28","author":"Carrieri","year":"2010","journal-title":"Urol Oncol"},{"key":"25","first-page":"4201","article-title":"Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer","volume":"29","author":"Carrieri","year":"2009","journal-title":"Anticancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Thalmann","year":"2011","journal-title":"Eur Urol"},{"key":"27","first-page":"1957","article-title":"Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder","volume":"7","author":"Liu","year":"2001","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.10808","article-title":"Does HER2\/neu expression provide prognostic information in patients with advanced urothelial carcinoma?","volume":"95","author":"DeVere-White","year":"2002","journal-title":"Cancer"},{"key":"29","volume-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"Reuter","year":"2016"},{"key":"30","volume-title":"AJCC Cancer Staging Manual","author":"Trotti","year":"2010","edition":"7th"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T14:37:51Z","timestamp":1589121471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,4,11]]}},"alternative-id":["15989","28445991"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15989","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]}}}